S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:INOInovio Pharmaceuticals Stock Price, Forecast & News

$14.78
+0.39 (+2.71 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.51
Now: $14.78
$16.06
50-Day Range
$14.62
MA: $23.11
$31.69
52-Week Range
$1.91
Now: $14.78
$33.79
Volume22.18 million shs
Average Volume32.54 million shs
Market Capitalization$2.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More
Inovio Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.11 million
Book Value$0.05 per share

Profitability

Net Income$-119,360,000.00
Net Margins-4,700.42%

Miscellaneous

Employees281
Market Cap$2.48 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$14.78
+0.39 (+2.71 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

How has Inovio Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INO shares have increased by 76.6% and is now trading at $14.78.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Inovio Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inovio Pharmaceuticals
.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.66. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $2.61 million. Inovio Pharmaceuticals had a negative return on equity of 166.85% and a negative net margin of 4,700.42%. The company's revenue for the quarter was up 100.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.30) EPS.
View Inovio Pharmaceuticals' earnings history
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

10 equities research analysts have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $4.00 to $31.00. On average, they expect Inovio Pharmaceuticals' share price to reach $14.00 in the next twelve months. This suggests that the stock has a possible downside of 5.3%.
View analysts' price targets for Inovio Pharmaceuticals
.

Has Inovio Pharmaceuticals been receiving favorable news coverage?

Headlines about INO stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of -1.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Inovio Pharmaceuticals
.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 26,350,000 shares, an increase of 15.0% from the May 14th total of 22,920,000 shares. Based on an average daily trading volume, of 35,230,000 shares, the days-to-cover ratio is presently 0.7 days.
View Inovio Pharmaceuticals' Short Interest
.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), Sorrento Therapeutics (SRNE), Tesla (TSLA) and Johnson & Johnson (JNJ).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 56)
  • Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
  • Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
  • Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.06%), Coatue Management LLC (1.74%), Wasatch Advisors Inc. (1.34%), Bank of New York Mellon Corp (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.37%) and Goldman Sachs Group Inc. (0.34%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau and Peter Kies.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Wasatch Advisors Inc., Defender Capital LLC., Tocqueville Asset Management L.P., SeaCrest Wealth Management LLC, Tudor Investment Corp Et Al, and US Bancorp DE. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim, Laurent Humeau, and Peter Kies.
View insider buying and selling activity for Inovio Pharmaceuticals
.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Coatue Management LLC, Swiss National Bank, Bank of New York Mellon Corp, Tekla Capital Management LLC, WINTON GROUP Ltd, California Public Employees Retirement System, and Federated Hermes Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau.
View insider buying and selling activity for Inovio Pharmaceuticals
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $14.78.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $2.48 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.